Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).

Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M, Houldsworth J, Najfeld V, El Jamal S, Petersen B, Moshier E, Hoffman R.

Leuk Res. 2020 Jan;88:106272. doi: 10.1016/j.leukres.2019.106272. Epub 2019 Nov 16.

PMID:
31778911
2.

Mutation profile of high-grade appendiceal mucinous neoplasm.

Liao X, Vavinskaya V, Sun K, Hao Y, Li X, Valasek M, Xu R, Polydorides AD, Houldsworth J, Harpaz N.

Histopathology. 2020 Feb;76(3):461-469. doi: 10.1111/his.13986. Epub 2019 Dec 23.

PMID:
31491041
3.

Clinicopathological and Molecular Characterization of Crohn's Disease-Associated Small Bowel Adenocarcinomas.

Liao X, Li G, McBride R, Houldsworth J, Harpaz N, Polydorides AD.

J Crohns Colitis. 2019 Aug 7. pii: jjz135. doi: 10.1093/ecco-jcc/jjz135. [Epub ahead of print]

PMID:
31388669
4.

Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma.

Hao Y, Khaykin D, Machado L, van den Akker T, Houldsworth J, Barlogie B, Hussein S, El Jamal SM, Petersen B, Teruya-Feldstein J.

Mod Pathol. 2020 Feb;33(2):188-195. doi: 10.1038/s41379-019-0333-6. Epub 2019 Aug 2.

PMID:
31375765
5.

Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: A case-control study.

Liao X, Hao Y, Zhang X, Ward S, Houldsworth J, Polydorides AD, Harpaz N.

PLoS One. 2019 Feb 7;14(2):e0212142. doi: 10.1371/journal.pone.0212142. eCollection 2019.

6.

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.

Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N.

PLoS One. 2019 Jan 25;14(1):e0210415. doi: 10.1371/journal.pone.0210415. eCollection 2019.

7.

Polypoid Undifferentiated Carcinoma With Osteoclast-like Giant Cells Arising in the Distal Common Bile Duct: A Rare Case Report.

Liao X, Houldsworth J, Luo J, Harpaz N, Zhu H.

Anticancer Res. 2019 Jan;39(1):437-441. doi: 10.21873/anticanres.13131.

PMID:
30591492
8.

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.

Wang X, Hu CS, Petersen B, Qiu J, Ye F, Houldsworth J, Eng K, Huang F, Hoffman R.

Blood Adv. 2018 Sep 25;2(18):2378-2388. doi: 10.1182/bloodadvances.2018022012.

9.

Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.

Coltoff A, Houldsworth J, Keyzner A, Renteria AS, Mascarenhas J.

Ann Hematol. 2018 Jul;97(7):1155-1167. doi: 10.1007/s00277-018-3330-9. Epub 2018 Apr 27. Review.

PMID:
29704019
10.

Amplification of specific chromosomal regions assessed by fluorescent in situ hybridization on Pap smears to be added as screening tool for identifying women at risk of progressing to cervical cancer.

Upendram P, Sahni S, Mohiuddin K, Poornima S, Gourishankar B, Kumar Vattam K, Boddala P, Jayashankar E, Mohiuddin S, Kamineni V, Mohan V, Houldsworth J, Hasan Q.

Tumour Biol. 2017 Oct;39(10):1010428317698363. doi: 10.1177/1010428317698363.

PMID:
28990460
11.

NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.

Su X, Zhang J, Mouawad R, CompĂ©rat E, RouprĂȘt M, Allanic F, Parra J, Bitker MO, Thompson EJ, Gowrishankar B, Houldsworth J, Weinstein JN, Tost J, Broom BM, Khayat D, Spano JP, Tannir NM, Malouf GG.

Cancer Res. 2017 Sep 15;77(18):4835-4845. doi: 10.1158/0008-5472.CAN-17-0143. Epub 2017 Jul 28.

12.

Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.

Siddiqi IN, Friedman J, Barry-Holson KQ, Ma C, Thodima V, Kang I, Padmanabhan R, Dias LM, Kelly KR, Brynes RK, Kamalakaran S, Houldsworth J.

Mod Pathol. 2016 Jun;29(6):570-81. doi: 10.1038/modpathol.2016.51. Epub 2016 Mar 11.

13.

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach.

Korkola JE, Heck S, Olshen AB, Feldman DR, Reuter VE, Houldsworth J, Bosl GJ, Chaganti RS.

PLoS One. 2015 Dec 1;10(12):e0142846. doi: 10.1371/journal.pone.0142846. eCollection 2015.

14.

Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.

Dias LM, Thodima V, Friedman J, Ma C, Guttapalli A, Mendiratta G, Siddiqi IN, Syrbu S, Chaganti RS, Houldsworth J.

Leuk Lymphoma. 2016;57(4):899-908. doi: 10.3109/10428194.2015.1080364. Epub 2015 Nov 16.

15.

A genomic algorithm for the molecular classification of common renal cortical neoplasms: development and validation.

Gowrishankar B, Przybycin CG, Ma C, Nandula SV, Rini B, Campbell S, Klein E, Chaganti RS, Magi-Galluzzi C, Houldsworth J.

J Urol. 2015 May;193(5):1479-85. doi: 10.1016/j.juro.2014.11.099. Epub 2014 Dec 11.

PMID:
25498568
16.

Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency.

Kushwaha R, Jagadish N, Kustagi M, Tomishima MJ, Mendiratta G, Bansal M, Kim HR, Sumazin P, Alvarez MJ, Lefebvre C, Villagrasa-Gonzalez P, Viale A, Korkola JE, Houldsworth J, Feldman DR, Bosl GJ, Califano A, Chaganti RS.

Stem Cells. 2015 Feb;33(2):367-77. doi: 10.1002/stem.1870.

17.

FHACT: the FISH-based HPV-associated cancer test that detects nonrandom gain at four genomic loci as biomarkers of disease progression.

Houldsworth J.

Expert Rev Mol Diagn. 2014 Nov;14(8):921-34. doi: 10.1586/14737159.2014.965685. Epub 2014 Oct 11. Review.

PMID:
25308338
18.

Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization.

Gowrishankar B, Cahill L, Arndt AE, Al-Ahmadie H, Lin O, Chadalavada K, Chaganti S, Nanjangud GJ, Murty VV, Chaganti RS, Reuter VE, Houldsworth J.

BJU Int. 2014 Dec;114(6):881-90. doi: 10.1111/bju.12643. Epub 2014 Jul 15.

19.

Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.

Houldsworth J, Guttapalli A, Thodima V, Yan XJ, Mendiratta G, Zielonka T, Nanjangud G, Chen W, Patil S, Mato A, Brown JR, Rai K, Chiorazzi N, Chaganti RS.

Leuk Lymphoma. 2014 Apr;55(4):920-8. doi: 10.3109/10428194.2013.845882. Epub 2013 Nov 12.

20.

Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results.

Luhn P, Houldsworth J, Cahill L, Schiffman M, Castle PE, Zuna RE, Dunn ST, Gold MA, Walker J, Wentzensen N.

Gynecol Oncol. 2013 Sep;130(3):595-600. doi: 10.1016/j.ygyno.2013.06.005. Epub 2013 Jun 13.

21.

Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.

Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin M, Barchi M.

PLoS One. 2012;7(12):e51563. doi: 10.1371/journal.pone.0051563. Epub 2012 Dec 12.

22.

Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.

Korkola JE, Houldsworth J, Bosl GJ, Chaganti RS.

BJU Int. 2009 Nov;104(9 Pt B):1334-8. doi: 10.1111/j.1464-410X.2009.08855.x. Review.

23.

NCCN task force report: molecular markers in leukemias and lymphomas.

Radich JP, Zelenetz AD, Chan WC, Croce CM, Czuczman MS, Erba HP, Horning SJ, Houldsworth J, Smith BD, Snyder DS, Sundar HM, Wetzler M, Winter JN.

J Natl Compr Canc Netw. 2009 Jul;7 Suppl 4:S1-34, quiz S35-6. Review.

PMID:
19635230
24.

Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.

Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, Patil S, Reuter VE, Bosl GJ, Chaganti RS.

J Clin Oncol. 2009 Nov 1;27(31):5240-7. doi: 10.1200/JCO.2008.20.0386. Epub 2009 Sep 21.

25.

Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas.

Gopalan A, Dhall D, Olgac S, Fine SW, Korkola JE, Houldsworth J, Chaganti RS, Bosl GJ, Reuter VE, Tickoo SK.

Mod Pathol. 2009 Aug;22(8):1066-74. doi: 10.1038/modpathol.2009.66. Epub 2009 Apr 24.

26.

Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.

Houldsworth J, Petlakh M, Olshen AB, Chaganti RS.

Leuk Lymphoma. 2008 Nov;49(11):2170-80. doi: 10.1080/10428190802428369.

PMID:
19021061
27.

In vivo differentiation and genomic evolution in adult male germ cell tumors.

Korkola JE, Heck S, Olshen AB, Reuter VE, Bosl GJ, Houldsworth J, Chaganti RS.

Genes Chromosomes Cancer. 2008 Jan;47(1):43-55.

PMID:
17943972
28.

Lack of A563G (I188V) missense mutation in RIZ/ PRDM2 in human diffuse large B-cell lymphomas.

Tam W, Gomez MF, Chadburn A, Knowles DM, Houldsworth J.

Genes Chromosomes Cancer. 2007 Apr;46(4):416-8. No abstract available.

PMID:
17205536
29.

Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.

Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR.

Blood. 2007 Apr 15;109(8):3409-16. Epub 2006 Dec 19.

30.

Biology and genetics of adult male germ cell tumors.

Houldsworth J, Korkola JE, Bosl GJ, Chaganti RS.

J Clin Oncol. 2006 Dec 10;24(35):5512-8.

PMID:
17158536
31.

Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells.

Chadalavada RS, Korkola JE, Houldsworth J, Olshen AB, Bosl GJ, Studer L, Chaganti RS.

Stem Cells. 2007 Mar;25(3):771-8. Epub 2006 Nov 30.

32.

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.

Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R.

J Exp Med. 2006 Feb 20;203(2):311-7.

33.

Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors.

Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS.

Cancer Res. 2006 Jan 15;66(2):820-7.

34.

Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas.

Chen W, Houldsworth J, Olshen AB, Nanjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein J, Zelenetz AD, Chaganti RS.

Blood. 2006 Mar 15;107(6):2477-85. Epub 2005 Nov 29.

35.

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

Moskowitz CH, Zelenetz AD, Kewalramani T, Hamlin P, Lessac-Chenen S, Houldsworth J, Olshen A, Chaganti R, Nimer S, Teruya-Feldstein J.

Blood. 2005 Nov 15;106(10):3383-5. Epub 2005 Aug 9.

PMID:
16091454
36.

Gene expression-based classification of nonseminomatous male germ cell tumors.

Korkola JE, Houldsworth J, Dobrzynski D, Olshen AB, Reuter VE, Bosl GJ, Chaganti RS.

Oncogene. 2005 Jul 28;24(32):5101-7.

PMID:
15870693
37.

Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells.

Chadalavada RS, Houldsworth J, Olshen AB, Bosl GJ, Studer L, Chaganti RS.

Funct Integr Genomics. 2005 Apr;5(2):59-69. Epub 2005 Feb 3.

PMID:
15690164
38.

Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.

Xiao Q, Shen N, Hedvat CV, Moskowitz CH, Sussman LK, Filippa DA, Zelenetz AD, Houldsworth J, Chaganti RS, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):211-5.

PMID:
15551733
39.

Expression of the AID protein in normal and neoplastic B cells.

Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, Chaganti RS, Dalla-Favera R.

Blood. 2004 Nov 15;104(10):3318-25. Epub 2004 Aug 10.

PMID:
15304391
40.

Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors.

Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, Assaad AM, Mansukhani M, Reuter VE, Bosl GJ, Chaganti RS, Murty VV.

Mol Cancer. 2004 May 18;3:16.

41.

Chemotherapy for teratoma with malignant transformation.

Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RS, Bosl GJ.

J Clin Oncol. 2003 Dec 1;21(23):4285-91.

PMID:
14645417
42.

Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas.

Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palanisamy N, Shen Y, Dyomina K, Petlakh M, Pan Q, Zelenetz AD, Dalla-Favera R, Chaganti RS.

Blood. 2004 Mar 1;103(5):1862-8. Epub 2003 Nov 13.

PMID:
14615382
43.

MUC-1 mucin protein expression in B-cell lymphomas.

Teruya-Feldstein J, Donnelly GB, Goy A, Hegde A, Nanjangud G, Qin J, Thaler H, Gilles F, Dyomin VG, Lloyd KO, Zelenetz AD, Houldsworth J, Chaganti RS.

Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):28-32.

PMID:
12610353
44.

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R.

Blood. 2003 Apr 15;101(8):2914-23. Epub 2002 Dec 19.

PMID:
12515714
45.

Characteristic promoter hypermethylation signatures in male germ cell tumors.

Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, Bosl GJ, Chaganti RS, Murty VV.

Mol Cancer. 2002 Nov 28;1:8.

46.

Genetics and biology of male germ cell tumors.

Houldsworth J.

Chest Surg Clin N Am. 2002 Nov;12(4):629-43. Review.

PMID:
12471867
47.

Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells.

Houldsworth J, Heath SC, Bosl GJ, Studer L, Chaganti RS.

Cell Growth Differ. 2002 Jun;13(6):257-64.

48.

Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma.

Palanisamy N, Abou-Elella AA, Chaganti SR, Houldsworth J, Offit K, Louie DC, Terayu-Feldstein J, Cigudosa JC, Rao PH, Sanger WG, Weisenburger DD, Chaganti RS.

Genes Chromosomes Cancer. 2002 Feb;33(2):114-22.

PMID:
11793437
49.

Expression of ID genes in differentiated elements of human male germ cell tumors.

Albanese JM, Reuter VE, Bosl GJ, Houldsworth J, Chaganti RS.

Diagn Mol Pathol. 2001 Dec;10(4):248-54.

PMID:
11763316
50.

Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas.

Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Houldsworth J, Chaganti RS.

Oncogene. 2001 Nov 15;20(52):7686-93.

Supplemental Content

Loading ...
Support Center